AlphAIAlphAI — Financial news for AI agents
gurufocus.com$JNJ

Is Johnson & Johnson (JNJ) Overvalued After Q3 Earnings Miss? GF

Johnson & Johnson (JNJ) reported Q3 2026 sales of $25.4B, up 5.9% YoY, but net earnings dropped 95.9% to $210M due to litigation and acquisition costs. Adjusted EPS of $2.59 beat estimates. The company raised its 2026 sales and EPS guidance. GuruFocus values JNJ at $194.36, suggesting it is 35.7% overvalued.

Original reporting
gurufocus.com
Published Oct 13, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 1:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$JNJ
Bearish
high confidence
Mentioned
$JNJ
Relevance
8/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$JNJBearishHigh
01

Why it matters

The earnings release combines a sharp GAAP profit decline with an adjusted EPS beat and higher guidance, creating mixed market signals.

02

Market read

The earnings miss on GAAP EPS is likely to weigh on JNJ's stock today, though the raised guidance may cushion the decline.

03

What to watch

Insider selling of $154.9 M may signal internal concerns; the special charge for talc litigation resolution could be a one‑time hit.

Relevance 8/10Novelty 9/10Timing: pre‑market today

Background

Johnson & Johnson disclosed Q3 2026 results via an 8‑K filing, highlighting a special charge for talc litigation and acquisition costs, while raising full‑year sales and EPS guidance.

Company-level read

Ticker impact

$JNJBearishHigh confidence
Context

Q3 2026 earnings released with a 95.9% drop in GAAP EPS to $0.09 versus $2.12 a year ago and adjusted EPS of $2.59 beating estimates, plus raised 2026 guidance.

Expected impact

likely pressure as investors price in the large GAAP earnings miss despite higher guidance

Evidence & confidence

The stark GAAP EPS decline signals short‑term weakness, while the upward guidance may limit the downside, creating mixed sentiment and short‑term sell pressure.

Market effects

Sector

Healthcare sector may see modest pullback as a large cap reports a GAAP earnings miss, but the guidance raise could support peers with strong pipelines.

Regional

U.S. market may open lower in health‑care stocks, with JNJ leading the move.

Global

Limited to global health‑care investors; no broader macro impact.

Counterpoint

What could challenge this read

The adjusted earnings beat and raised guidance suggest the GAAP miss is a one‑off; a contrarian could look for a bounce.

Key entities

  • company
    Johnson & Johnson

    Diversified health‑care conglomerate reporting Q3 2026 results.

  • company
    Firefly Bio, Inc.

    Acquisition target contributing to special charges.

  • company
    Sail Biomedicines

    Strategic partner mentioned in the filing.

Read at source← All news

StoryJohnson & Johnson posts Q3 profit plunge but raises full‑year 2026 outlook

Also covered by

6 outlets

Related articles

$ZBHHighAI 9/10

Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, “Validating the Progress” of Its Strategy

Zimmer Biomet (ZBH) shares rose 15% after Q3 sales grew 3.7% in constant currency, with hips, sports medicine, and technology segments growing 7% or more. The company raised its 2026 guidance, citing progress in diversification. Knees, 37% of sales, declined 2.6%. Rival Stryker (SYK) and Smith & Nephew (SNN) also saw gains, despite Smith & Nephew cutting its outlook.

finance.yahoo.com
$JNJMedAI 8/10

Johnson & Johnson’s Javelin Catheter Met Both Trial Goals and Its Impella Data Pushed Back on a Negative Study. Here’s What It Doesn’t Settle

Johnson & Johnson (JNJ) reported positive results for its Javelin catheter, meeting both primary goals in a pivotal study. Impella heart pump data showed lower death rates than a previous negative study. Javelin is still under FDA review, and Impella's recovery depends on future trials. JNJ's cardiovascular unit saw a sales decline, with Impella contributing 1.6% of total revenue. Analysts project a ~25% total return for JNJ stock.

finance.yahoo.com
$JNJMed

TREMFYA® (guselkumab) reimbursed for the treatment of moderately to severely active Crohn’s disease and ulcerative colitis for use in Ireland

Johnson & Johnson's TREMFYA (guselkumab) has been approved for reimbursement in Ireland for treating moderately to severely active Crohn’s disease and ulcerative colitis. The approval is based on Phase 3 trials showing significant clinical remission rates. According to the company, it offers a novel dual mechanism of action and improved outcomes for patients.

imt.ie
$JNJMed

J&J data show lower mortality with Impella in HRPCI than CHIP-BCIS3

Johnson & Johnson (J&J) presented data at a symposium showing lower mortality rates in high-risk PCI patients using Impella heart pumps compared to the CHIP-BCIS3 trial. Three analyses, involving 1,379 patients, reported 30-day mortality rates of 6.1% and 4.7%, and 90-day rates of 6.5%. J&J's heart recovery chief medical officer highlighted the importance of device usage and patient selection. The company continues studying Impella, with PROTECT IV trial results expected in 2027.

medicaldevice-network.com
$JNJHigh

PROTEUS: Perioperative Apalutamide Plus ADT Improves EFS in High-Risk Locally Advanced Prostate Cancer

A substudy of the phase 3 PROTEUS trial, presented at ESMO Congress 2026, showed that perioperative apalutamide plus ADT reduced recurrence or death risk by 62% in high-risk prostate cancer patients. The study, supported by Johnson & Johnson, met primary endpoints, including event-free survival and metastasis-free survival. Lead author Alberto Briganti suggested the treatment could become a standard option for eligible patients.

endocrinologyadvisor.com